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Figure 1. MRI of the brain, showing lesions caused by Epstein-Barr virus encephalitis
the virus) a few days after transplantation
[2–4], but, in our patient, reactivation
occurred almost 8 years after transplan-
tation. However, as described in previous
reports [1, 4, 5], PCR detection of viral
DNA in CSF samples allowed for diag-
nosis of the disease, which had already
been entertained on the basis of the clin-
ical features. The PCR results also ex-
cluded the diagnosis of encephalitis due
to other viruses, such as herpes simplex
virus, CMV, or human herpesvirus 6.
Successful treatment with intravenous
ganciclovir has been reported in other
cases of encephalitis caused by EBV [3].
Our observations support those findings
and emphasize the importance of starting
treatment as soon as the disease is sus-
pected on the basis of clinical features,
because encephalitis caused by EBV can
have considerable neurological sequelae
and can be fatal.
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HIV Lipoatrophy and
Mosquito Bites
Sir—In the summer of 1999, several pa-
tients infected with HIV type 1 described
to us an increase in the frequency of mos-
quito bites received since being treated
with potent antiretroviral therapy (ART).
To analyze this possibility, we performed
a prospective cross-sectional study aimed
at identifying an eventual association be-
tween ART and mosquito bites.
During 4 consecutive weeks (Au-
gust–September), 122 HIV-infected pa-
tients who were seen in our outpatient
HIV clinic and received treatment were
included in the study. Data on prevalence
of mosquito bites, demographics, CD4
count, HIV load, type of ART received,
and ART-associated adverse events were
collected using a standardized question-
naire. Multivariate logistic regression was
performed using STATA software, version
6.0 (Stata Corporation).
Seventy-four patients (61%) described
having received 1 or more mosquito bites
during the 3 months before the study. A
total of 28 patients reported that, com-
pared with people in their immediate en-
vironment, they had a greater suscepti-
bility to being bitten by mosquitoes. Ten
patients believed that they were more
susceptible to being bitten since having
tested positive for HIV infection, and 12
believed that such susceptibility had in-
creased since they began receiving ART.
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Mosquito bites were observed on 18 pa-
tients (14.8%), 7 of whom had 5 bite
marks. Using a multivariate logistic re-
gression model adjusted for age, sex, CD4
count, HIV load, and HIV-transmission
group, we identified an independent as-
sociation between lipoatrophy and (1) a
history of having been bitten by mos-
quitoes in the 3 months before the study
(OR, 2.44; 95% CI, 1.06–5.59) and (2)
the presence of mosquito bites at the time
of physical examination (OR, 10.13; 95%
CI, 2.65–38.73). No specific type of ART
was found to be associated with mos-
quito bites.
Lipoatrophy has been increasingly de-
scribed among individuals who receive
nucleoside reverse-transcriptase inhibi-
tors [1]. Lipoatrophic subcutaneous tis-
sue may present a more accessible cap-
illary network and an increased release of
volatile substances from the skin surface.
A similar mechanism, triggered by in-
creased blood flow, has been suggested as
an explanation for the attraction of mos-
quitoes to the skin of pregnant women
[2, 3]. Whether the observed increase in
mosquito bites may result in greater risk
for insectborne infections, such as those
caused by Leishmania and Plasmodium
species, can only be speculated. The as-
sociation of lipoatrophy with an increase
in mosquito bites has no bearing on HIV
transmission, because insect vectors play
no role in the spread of HIV [4].
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Recurrent Nonmenstrual
Toxic Shock
Sir—Andrews et al. [1] recently published
a review entitled “Recurrent Nonmen-
strual Toxic Shock Syndrome: Clinical
Manifestations, Diagnosis and Treat-
ment.” As their title suggests, although
recurrent menstrual toxic shock is not
uncommon, few reports of this syndrome
have been published. The authors review
9 previous cases and report 3 of their
own, including 1 in a patient with AIDS.
In 1992 we described 5 patients with
a recalcitrant, erythematous desquama-
tive disorder associated with toxic shock
toxin-1 (3 patients), staphylococcal en-
terotoxin A (1 patient) and staphylococ-
cal enterotoxin B (1 patient) [2]. Three
of the 5 patients died; autopsies of 2 pa-
tients confirmed residual staphylococcal
infection, and, interestingly, both survi-
vors developed recurrent disease. All pa-
tients were homosexual men. One of the
patients significantly improved after re-
ceiving commercial iv gammaglobulin,
which contains staphylococcal toxin an-
tibody [3]. Indeed, the HIV-1–infected
patient treated by Andrews et al. [1] also
responded favorably to iv gammaglobulin.
We suggested that the recalcitrant, ery-
thematous desquamative disorder was re-
lated to defective chemotaxis [4], but ob-
served that a lack of staphylococcal toxin
antibody formation could also play a
role. Therefore, the disorder—the char-
acteristics of which have subsequently
been confirmed [5, 6]—may have an im-
munologic relationship to recurrent non-
menstrual toxic shock syndrome in pa-
tients infected with HIV-1; patients with
these disorders likely lack staphylococcal
toxin antibody production. The absence
of toxin antibody may be due to the “su-
perantigen” molecular behavior of staph-
ylococcal toxins.
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Antifungal Prophylaxis
and the Rate of
Bacteremia among
Neutropenic Patients
Sir—We recently published an article in
Clinical Infectious Diseases that explored
the possible association between antifun-
gal prophylaxis and the rate of docu-
mented bacteremia among febrile neu-
tropenic patients with cancer [1]. This
